The Food and Drug Administration (FDA) has approved the following new medication for the treatment of Helicobacter pylori (H. pylori) infection in adults.:
- Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin)
- Voquezna Dual Pak (vonoprazan, amoxicillin)
Vonoprazan, which gives the name of the medication, is an oral small molecule potassium-competitive acid blocker.
H. pylori eradication rates were 84.7% and 78.5% with Voquezna Triple and Dual Pak, respectively.
Voquezna Triple Pak is supplied as a carton containing 56-tablets and 56-capsules divided into 14 daily dose blister cards. Each daily blister card contains 2 vonoprazan tablets (20mg each), 4 amoxicillin capsules (500mg each), and 2 clarithromycin tablets (500mg each).
Voquezna Dual Pak is supplied as a carton containing 28-tablets and 84-capsules divided into 14 daily dose blister cards. Each daily blister card contains 2 vonoprazan tablets (20mg each) and 6 amoxicillin capsules (500mg each).
References:
https://www.empr.com/home/news/voquezna-triple-dual-pak-approved-for-h-pylori-infection-treatment/
New option for H pylori treatment: Voquezna
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment